共 19 条
[1]
Chow L., De Gasparo M., Levens N., Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors, Europ J Pharmacol, 282, pp. 77-86, (1995)
[2]
Delacretaz E., Nussberger J., Biollaz J., Waeber B., Brunner H.R., Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers, Hypertension, 25, pp. 14-21, (1995)
[3]
Ferrari P., Rosman J., Weidmann P., Antihypertensive agents, serum lipoproteins and glucose metabolism, Am J Cardiol, 67, (1991)
[4]
Goa K.L., Wagstaff A.J., Losartan potassium: A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension, Drugs, 51, pp. 820-845, (1996)
[5]
Herings R.M., De Boer A., Stricker B.H., Leufkens H.G., Porsius A., Hypoglyeaemia associated with use of inhibitors of angiotensin converting enzyme, Lancet, 345, pp. 1195-1198, (1995)
[6]
Iimura O., Shimamoto K., Matsuda K., Effects of angiotensin receptor antagonists and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives, Am J Hypertens, 8, pp. 353-357, (1995)
[7]
The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V), Arch Intern Med, 153, pp. 154-183, (1993)
[8]
Kannel W.B., Potency of vascular risk factors as the basis for antihypertensive therapy, European Heart Journal, 13, SUPPL. G, pp. 34-42, (1992)
[9]
Kaplan N.M., Combination therapy for systemic hypertension, Am J Cardiol, 76, pp. 595-597, (1995)
[10]
Laakso M., Karjalainen L., Lempiainen-Kuosa P., Effects of losartan on insulin sensitivity in hypertensive subjects, Hypertension, 28, 3, pp. 392-396, (1996)